An inhibitor of HDAC1, -2, and -3
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

CI-994

Item No. 12084

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-(acetylamino)-N-(2-aminophenyl)-benzamide
CAS Number
112522-64-2
Synonyms
  • N-Acetyldinaline
  • Goe 5549
  • PD 123654
  • Tacedinaline
Molecular Formula
C15H15N3O2
Formula Weight
269.3
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 1 mg/mlDMSO: 5 mg/mlDMSO:PBS (pH 7.2) (1:5): 0.5 mg/ml
λmax
271 nm
SMILES
O=C(NC1=C(N)C=CC=C1)C2=CC=C(NC(C)=O)C=C2
InChi Code
InChI=1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)
InChi Key
VAZAPHZUAVEOMC-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $26

    Add

    10 mg

    $48

    Add

    50 mg

    $195

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    CI-994 is an inhibitor of histone deacetylase 1 (HDAC1), HDAC2, and HDAC3 (IC50s = 0.9, 0.9, and 1.2 µM, respectively).1 It is selective for these HDACs over HDAC8 (IC50 = >20 µM). CI-994 inhibits the growth of HCT116 colon cancer cells but not human mammary epithelial cells (HMECs; IC50s = 4 and >50 µM, respectively). In vivo, CI-994 (11.85 mg/kg twice per day) increases survival time in a rat model of 9,10-dimethyl-1,2-benzathracene-induced leukemia.2 It reduces tumor growth in an LNCaP mouse xenograft model, as well as in a Panc02 murine pancreatic cancer model.3 CI-994 (1, 10, and 30 mg/kg) reduces neutrophil accumulation, inflammatory cytokine expression, and neuronal loss in a mouse model of spinal cord injury.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Moradei, O.M., Mallais, T.C., Frechette, S., et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J. Med. Chem. 50(23), 5543-5546 (2007).

    2. El-Beltagi, H.M., Martens, A.C.M., Lelieveld, P., et al. Acetyldinaline: A new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells—preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res. 53(13), 3008-3014 (1993).

    3. LoRusso, P.M., Demchik, L., Foster, B., et al. Preclinical antitumor activity of CI-994. Invest. New Drugs 14(4), 349-356 (1996).

    4. Zhang, S., Fujita, Y., Matsuzaki, R., et al. Class I histone deacetylase (HDAC) inhibitor CI-994 promotes functional recovery following spinal cord injury. Cell Death Dis. 9(5), 460 (2018).